Safety and Immunogenicity Study of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17
Random, Double Blind, Placebo Controlled Phase I Clinical Trials to Estimate the Safety and Preliminary Immunogenicity of Tetravalent Recombinant Human Papilloma Virus Vaccine (6,11,16,18 Type)(Hansenula Polymorpha) in Women of 9 to 30 Years Old and Men of 9 to 17 Years Old
Sponsor: Beijing Chaoyang District Centre for Disease Control and Prevention
This PHASE1 trial investigates Cervical Cancer and is currently ongoing. Beijing Chaoyang District Centre for Disease Control and Prevention leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Sep 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Not Yet Recruiting → Unknown Status
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Chaoyang District Centre for Disease Control and Prevention
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.